Status:
WITHDRAWN
Anti-arrhythmic Medication v. MRI-Merge Ablation in the Treatment of Ventricular Tachycardia
Lead Sponsor:
Johns Hopkins University
Conditions:
Ventricular Tachycardia
Eligibility:
All Genders
18-99 years
Phase:
NA
Brief Summary
Ventricular tachycardia (VT) is a morbid arrhythmia responsible for many sudden deaths and ICD shocks. Despite much progress in the treatment of arrhythmia, VT remains a therapeutic challenge. Most pa...
Eligibility Criteria
Inclusion
- Inclusion:
- Current treatment with amiodarone
- Ischemic or non-ischemic cardiomyopathy
- Monomorphic ventricular tachycardia at any cycle length, with \> 1 occurrence of the same cycle length and morphology, at least one episode needs to be of sufficient duration to result in a shock.
- No contraindication to up titration of meds or to VT radiofrequency ablation (RFA)
- Exclusion:
- Primary antiarrhythmic medication other than amiodarone
- Amiodarone at dose of 600 mg daily or higher
- Polymorphic VT as culprit rhythm
- History of metal exposure (welding)
- Pregnant women
- Recent myocardial infarction
- Planned coronary revascularization
- Implantable cardiac devices not previously tested for safety in the setting of MRI
- Glomerular Filtration Rate (GFR) \< 30 ml/min
Exclusion
Key Trial Info
Start Date :
June 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00721032
Start Date
June 1 2012
End Date
August 1 2015
Last Update
May 10 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Oregon Health & Science University
Portland, Oregon, United States, 97239